Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be clinically effective to date. We explore the resistance mechanisms uniquely employed by malignant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ponz-Sarvise, Mariano, Corbo, Vincenzo, Tiriac, Hervé, Engle, Dannielle D., Frese, Kristopher K., Oni, Tobiloba E., Hwang, Chang-Il, Öhlund, Daniel, Chio, Iok In Christine, Baker, Lindsey A., Filippini, Dea, Wright, Kevin, Bapiro, Tashinga E., Huang, Pearl, Smith, Paul, Yu, Kenneth H., Jodrell, Duncan I, Park, Youngkyu, Tuveson, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858952/
https://ncbi.nlm.nih.gov/pubmed/31492749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1398
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados